I've asked that question but it's obviously something they can't/won't answer. Impairments over the past 5 years now total over $1,000,000,000 with not all but the bulk of that attributable to the $880M spent on the Teva generic portfolio. What is disappointing is that 2019 was the great 'reset' to use Roger Corbett's wording when impairments totalled $350M. The impression given at that time was that $350M should tidy up the balance sheet and be the end of the impairments ........
Intangibles totalled $1235M after the Teva purchase in 2017. There's been $1056M in impairments since then. Intangibles now showing $428M.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)